Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $3.5552W HIGH $16.11
Volume
760.67 K
Value Traded
6.54 M
Short % Float
7.8%
Days to Cover
1.7
+0.35%Week
+1.18%1 Month
+74.65%3 Month
+87.99%6 Month
-79.44%5 Year
-67.51%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
391.22 M
EPS (TTM)
-0.49
P/E Ratio
-
Ent. Value
332.06 M
Total Shares
45.44 M
Float Shares
34.49 M
Insiders
24.88%
Institutions
59.03%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|
PoA blends historical approval base rates, trial design score and FDA review track record.
YMAB Catalyst Timeline
Dated clinical, regulatory and corporate events for Y-mAbs Therapeutics, Inc.
Past FDA Catalysts and PDUFA Decisions
How YMAB actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2025-05-28 | GD2-SADA (Pretargeted Radioimmunotherapy) | Phase 1 data readout | Phase 1 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
Pipeline Score
Pipeline Value
Valuation Signal
1
Drugs Scored
rNPV / MCap
Top Drug
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Naxitamab Monoclonal antibodyMarketedNCT03189706 | Neuroblastoma | Approved | ACTIVE NOT_RECRUITING | 489 | Jun 1, 2026 | ||||||
| Naxitamab Monoclonal antibodyMarketedNCT07537400 | High-Risk Neuroblastoma | Approved | NOT YET_RECRUITING | 10 | Apr 1, 2032 | ||||||
| Radioactive iodine-labeled monoclonal antibody omburtamab Monoclonal antibodyCompletedNCT01502917 | Brain Cancer | Phase 1 | COMPLETED | 50 | Jan 1, 2022 | ||||||
| Humanized 3F8 Monoclonal Antibody Monoclonal antibodyMarketedNCT01419834 | Neuroblastoma | Approved | COMPLETED | 68 | Aug 2, 2023 |
Clinical Trial Results
Readouts, endpoints and source filings for every YMAB program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| naxitamab | relapsed/refractory high-risk neuroblastoma | Phase 2 | 2025-03-03 | overall response rate: 50%; complete response: 38%; partial response: 12%; bone compartment response: 58%; bone marrow compartment response: 74%; one year overall survival: 93%; one year progression free survival: 35%Read More | Y-mAbs Announces Publication of Phase 2 Interim Results in Nature CommunicationsRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Gad ThomasDirector, Officer (CHIEF BUSINESS OFFICER) | Option | 103,000 305,721 held | $2.00 | 06/03/2025 |
Hedge Fund 13F Activity
Hedge Funds invested in YMAB
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| Paradigm Biocapital Advisors LP | 0.8 % (-11.1 %) | 19.11 M | 4.24 M |
Ownership Trends
YMAB Short Interest
Shares sold short, counted twice a month.
7.8%
Short % of Float
of tradable shares sold short
1.1M
Shares Sold Short
-42.3% vs prior count
1.7 Low
Days to Cover
trading days of normal volume to buy every short share back
638.5K
Avg Daily Volume
the average used for days to cover
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How YMAB ranks across every disease it competes in
Competitive Position is a premium feature
See how YMAB ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialYMAB News
About Y-mAbs Therapeutics, Inc.
Founded2018
BIOPHARMAWATCH ELITE PLUS
Trade the next YMAB catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime